Pharma Mar
Pharma Mar, officially known as Pharma Mar S.A., is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in Madrid, Spain. Founded in 1986, the company has established itself as a leader in the development of innovative therapies derived from marine organisms, focusing primarily on oncology and rare diseases.
With a strong presence in Europe and expanding operations globally, Pharma Mar is renowned for its unique core products, including Yondelis (trabectedin), which has transformed treatment options for certain types of cancer. The company’s commitment to research and development has led to significant milestones, positioning it as a key innovator in the pharmaceutical landscape. Notably, Pharma Mar has garnered recognition for its contributions to cancer treatment, solidifying its market position as a trusted name in the industry.
+30 vs industry average
Pharma Mar’s score of 68 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Pharma Mar?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Pharma Mar's reported carbon emissions
Pharma Mar, a pharmaceutical preparation manufacturing company headquartered in Spain, is committed to reducing its carbon emissions. In the reporting year 2024, the company reported a total of approximately 17.7 million kg CO2e. This total comprises roughly 1.34 million kg CO2e from Scope 1 emissions and approximately 247,000 kg CO2e from Scope 2 (market-based) emissions. Scope 3 emissions represented the largest portion, totalling approximately 16.13 million kg CO2e. The company has set ambitious climate targets, including a commitment to reduce Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as a base year. Furthermore, Pharma Mar has committed to a long-term goal of reducing its total Scope 1, 2, and 3 emissions by 90% by 2050, also from a 2021 baseline. These targets align with keeping global warming to 1.5°C. The company's climate commitments have been validated by the Science Based Targets initiative (SBTi) under their streamlined route for small and medium-sized enterprises (SMEs).
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Pharma Mar’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Pharma Mar yet.
Scope 3 top emissions categories
8 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Pharma Mar
Frequently asked questions
Common questions about Pharma Mar’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project